Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant nivolumab plus nab-paclitaxel before cystectomy in muscle-invasive bladder cancer
2020-005050-20Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and nab-paclitaxel in muscle-invasive bladder cancer (MIBC) and bladder cancer, sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Pathologic complete response. Started Aug 2021; status: completed.
02
Drugs
nivolumabnab-paclitaxel
03
Conditions
muscle-invasive bladder cancer (MIBC)bladder cancer
Beyond the preview
Go deeper on 2020-005050-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005050-20.